ArticleCase reports in oncological medicine2025
A Case of Primary Pulmonary Meningioma With Genetic Characterization and Literature Review.
Article in Case reports in oncological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Primary pulmonary meningioma: a case report and literature review.International journal of surgery case reports · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary pulmonary meningiomas (PPMs) are exceptionally rare tumors, accounting for a small fraction of ectopic meningiomas found outside the central nervous system (CNS). These tumors are typically benign, with only 5%-8% being malignant. Since the first reported case in 1982, fewer than 100 cases have been documented. We report a unique case of PPM in a 58-year-old male detected incidentally during lung cancer screening. Histopathological and immunohistochemical (IHC) analysis confirmed the diagnosis, and next-generation sequencing (NGS) revealed a Neurofibromatosis Type 2 (NF2) inactivating mutation and a likely subclonal PALB2 mutation-findings not commonly reported in the PPM literature. Our comprehensive review of 70 reported cases reveals a female predominance, asymptomatic presentation in most cases, and strong IHC positivity for EMA, PR, and vimentin. Malignant cases tended to be larger and more symptomatic. Our case highlights the value of molecular profiling in differentiating PPMs from other pulmonary neoplasms and CNS metastases. Given the emerging role of NGS in identifying tumor-specific mutations, further exploration of the genetic landscape of PPMs is warranted. Recognition of NF2 mutations as potential drivers may open new avenues for targeted therapies and long-term monitoring strategies in affected individuals.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.